Aratana Therapeutics, Inc. announced the over-allotment option granted to Stifel and Lazard Capital Markets who acted as underwriters for the company. The purchase was for 862,500 additional shares of common stock, at a public offering with a price of US$6.00 per share. This is in connection with the previously announced initial public offering of 5,750,000 shares of common stock for Aratana. The total gross proceeds from the offering to amounted to US$39,675,000. Lazard and Stifel Capital Markets acted the lead book-running managers for the offering. Craig-Hallum Capital Group, William Blair and JMP Securities acted as co-managers for the deal

Aratana Therapeutics Inc is a biopharmaceutical company that develops medicines for cats and dogs or companion animals. The company focuses on licensing, commercialization and development of innovative prescription medicine for pets. Aratana's licenses proprietary, patent-protected compounds that are acquired from human pharmaceutical and biotechnology companies then develops strategies used in programs for animal health markets.